The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
Open accessAbstract
Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is for healthcare professionals to predict. However, recent evidence in genomic studies has pointed out the essential role that genetics could play in influencing person’s suicide risk. Combining genomic and clinical risk assessment approaches, some studies have identified a number of biomarkers for suicidal ideation, which are involved in neural connectivity, neural activity, mood, as well as in immune and inflammatory response, such as the mammalian target of rapamycin (mTOR) signaling. This interesting discovery provides the neurobiological bases for the use of drugs that impact these specific signaling pathways in the treatment of suicidality, such as ketamine. Ketamine, an N-methyl-d-aspartate glutamate (NMDA) antagonist agent, has recently hit the headlines because of its rapid antidepressant and concurrent anti-suicidal action. Here we review the preclinical and clinical evidence that lay the foundations of the efficacy of ketamine in the treatment of suicidal ideation in mood disorders, thereby also approaching the essential question of the understanding of neurobiological processes of suicide and the potential therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene
Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J., Mill, J., Martin, J., Braithwaite, A., et al. (2003) · Science · doi:10.1126/science.1083968 · Cited by 8,120 · cited 1×
“For example, a recent study—based on preclinical evidence of the association between the short allele of the 5-HTT (serotonin transporter) gene-linked polymorphic region and greater susceptibility to stress events [25–27]—tested the hypothesis that variants in the 5-HTT gene might influence dysfunctional adaptation to…”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“mTOR, indeed, represents an essential target of ketamine in the prefrontal cortex of animal models of depressive states, and the activation of mTOR by ketamine also provokes the increase in mRNA and protein levels of activity-regulated cytoskeletal-associated protein Arc, synapsin I, postsynaptic density protein 95 (P…”
BackgroundSerotonin transporter genetic variation and the response of the human amygdala.
Hariri, A. R., Mattay, V. S., Tessitore, A., Kolachana, B., Fera, F., Goldman, D., Egan, M. F., & Weinberger, D. R. (2002) · Science · doi:10.1126/science.1071829 · Cited by 2,340
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Indeed, in BDNF knock-out animals, ketamine is not able to produce antidepressant effects, thus demonstrating the crucial role of BDNF in fast-acting responses following ketamine administration [93].”
BackgroundInoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Psychiatric diagnoses in 3275 suicides: a meta-analysis
Arsenault-Lapierre, G., Kim, C., & Turecki, G. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-37 · Cited by 985
Koenigs, M., & Grafman, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.004 · Cited by 956 · cited 1×
“Functional studies have associated the deficits in cognitive flexibility showed by depressed patients to specific alterations in the structure and connection of the prefrontal cortex (PFC) [44,45].”
BackgroundHasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 1×
“Indeed, reduced glutamate/glutamine and GABA levels (positively correlated with each other) have been demonstrated in the prefrontal cortex of unmedicated depressed patients using proton magnetic resonance spectroscopy [46].”
BackgroundZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“[125], who demonstrated that the first effects on depressive symptoms and suicidal thoughts may be seen only 40 min after ketamine injection (0.”
Background
Cited by
Understanding the Complex of Suicide in Depression: from Research to Clinics
Orsolini, L., Latini, R., Pompili, M., Serafini, G., Volpe, U., Vellante, F., Fornaro, M., Valchera, A., Tomasetti, C., Fraticelli, S., et al. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0171 · Cited by 406
Self-citationPrevalence of post-traumatic stress disorder in the United States: a systematic literature review
Schein, J., Houle, C., Urganus, A., Cloutier, M., Patterson-Lomba, O., Wang, Y., King, S., Levinson, W., Guérin, A., Lefebvre, P., et al. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1978417 · Cited by 288
The lethality of suicide methods: A systematic review and meta-analysis
Cai, Z., Junus, A., Chang, Q., & Yip, P. S. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.054 · Cited by 155
Esketamine for Treatment-Resistant Depression: A Review of Clinical Evidence (Review)
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11810 · Cited by 82
“The identification of risk markers for suicidal behaviors by combining genomic assessment and clinical evaluation has led to an increased interest in drugs that may modulate mechanisms such as neural connectivity and activity, immune and inflammatory response (18).”
Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
Tomasetti, C., Montemitro, C., Fiengo, A. L. C., Santone, C., Orsolini, L., Valchera, A., Carano, A., Pompili, M., Serafini, G., Perna, G., et al. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190312102444 · Cited by 44
Self-citationInpatient suicide in psychiatric settings: Evaluation of current prevention measures
Chammas, F., Januel, D., & Bouaziz, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.997974 · Cited by 38
Sokolowski, M., & Wasserman, D. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.06.002 · Cited by 29
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Validation of the Acceptance and Action Questionnaire-II in the general Spanish population
Menéndez-Aller, Á., Cuesta, M., Postigo, Á., González-Nuevo, C., García-Fernández, J., & García-Cueto, E. (2023) · Current Psychology · doi:10.1007/s12144-021-02447-3 · Cited by 10
Metadata
- Authors
- De Berardis, D., Fornaro, M., Valchera, A., Cavuto, M., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Fiengo, A., Ventriglio, A., Yong-Ku, K., Martinotti, G., Di Giannantonio, M., & Tomasetti, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-09-23
- Volume
- 19
- Issue
- 10
- Pages
- 2888
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2890611676
- Cited by
- 174
- References
- 47
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.